A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism

Autor/inn/en	Chez, Michael; Kile, Shawn; Lepage, Christopher; Parise, Carol; Benabides, Bobbie; Hankins, Andrea
Titel	A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism
Quelle	In: Journal of Autism and Developmental Disorders, 50 (2020) 5, S.1532-1538 (7 Seiten) PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (Parise, Carol)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-018-3703-x
Schlagwörter	Outcomes of Treatment; Randomized Controlled Trials; Pilot Projects; Drug Therapy; Autism; Adults; Patients; Symptoms (Individual Disorders); Check Lists; Behavior Problems; Aggression; Aberrant Behavior Checklist + Suchen Sie Ihr Suchwort? Pilot project; Modellversuch; Pilotprojekt; Autismus; Patient; Psychiatrische Symptomatik; Checkliste
Abstract	Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F[subscript 1,10] = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism. (As Provided).
Anmerkungen	Springer. Available from: Springer Nature. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: customerservice@springernature.com; Web site: https://link.springer.com/
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01